Top Markets
#1 0G 0G +11.60%
#2 Siacoin Siacoin +9.25%
#3 Cash Cat Cash Cat +8.48%
#4 Arbitrum Arbitrum +7.02%
#5 MarsCoin MarsCoin +6.90%
#6 Asteroid Shiba Asteroid Shiba +6.90%
#7 Seeker Seeker +6.12%
#8 Metis Metis +6.04%
#9 Useless Coin Useless Coin +5.01%
#10 Optimism Optimism +4.77%
Coin of the day
0G 0G
Innstillinger
Språk
NORSK
Valuta
USD
Tema
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Rangering i aksjer #14109
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Aksjekurs
$1.46
Sist synkronisert: 2026-07-28
Markedsverdi
$435.25M
Endring (1 dag)
-2.34%
Endring (1 år)
-25.65%
Land
TW
Handel EirGenix Inc. (6589)

Kategori

Healthcare
EPS for EirGenix Inc. (6589)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til EirGenix Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for EirGenix Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH